Share

    


Home / Search Results

Search Results

You searched for:

In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.
In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.
As the oncology community’s understanding and knowledge of cancer continues to deepen, so too does awareness of the diverse concerns and needs of the nation’s growing population of cancer survivors. Fifteen years ago, with the release of the National Academy of Medicine’s consensus report, From Cancer Patient to Cancer Survivor: Lost in Transition, cancer care providers were challenged to respond …
In this episode, CANCER BUZZ speaks with Brittney Baer, BSN, RN, patient care coordinator, immune effector cells, at Vanderbilt University Medical Center’s Vanderbilt-Ingram Cancer Center about key strategies and solutions to prioritize patient quality of life by addressing barriers to holistic survivorship care.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
Rockville, MD—The Association of Community Cancer Centers (ACCC) announced today the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies. ACCC worked closely with a team of multispecialty thought leaders via the IO Institute Working Groups to develop …
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.
While the number of oncology patients and survivors is increasing, the growth of medical oncologists has lagged behind, and advanced practice providers (APPs) play a critical role in filling this care gap.
Learn the 10 feasible and impactful “how-tos” Summit participants identified within three domains—care coordination and communication, clinical trials, and acknowledging and mitigating implicit bias.
The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy …
In 2019 the Association of Community Cancer Centers developed an education program to provide all members of the multidisciplinary care team knowledge and resources to help successfully integrate immunotherapies into the treatment of patients with RCC.
ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.